Ovarian endometrioid adenocarcinoma: Incidence and clinical significance of the morphologic and immunohistochemical markers of mismatch repair protein defects and tumor microsatellite instability

American Journal of Surgical Pathology

Volumn 36, Issue 2, 2012, Pages 163-172

  Aysal, Anil ^a   Karnezis, Anthony ^a   Medhi, Irum ^a   Grenert, James P ^a   Zaloudek, Charles J ^a   Rabban, Joseph T ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Lynch syndrome; Microsatellite instability; Mismatch repair proteins; Ovarian cancer; Tumor infiltrating lymphocytes

Indexed keywords

ADENOSINE TRIPHOSPHATASE; DNA BINDING PROTEIN; G T MISMATCH BINDING PROTEIN; G-T MISMATCH-BINDING PROTEIN; MLH1 PROTEIN, HUMAN; MSH2 PROTEIN, HUMAN; NUCLEAR PROTEIN; PMS2 PROTEIN, HUMAN; POLYDEOXYRIBONUCLEOTIDE SYNTHASE; PROTEIN MSH2; SIGNAL TRANSDUCING ADAPTOR PROTEIN;

ADULT; AGED; ARTICLE; ENDOMETRIOID CARCINOMA; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; MICROSATELLITE INSTABILITY; MIDDLE AGED; MISMATCH REPAIR; OVARY TUMOR; PATHOLOGY; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADENOSINE TRIPHOSPHATASES; ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, ENDOMETRIOID; DNA MISMATCH REPAIR; DNA REPAIR ENZYMES; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTES, TUMOR-INFILTRATING; MICROSATELLITE INSTABILITY; MIDDLE AGED; MUTS HOMOLOG 2 PROTEIN; NUCLEAR PROTEINS; OVARIAN NEOPLASMS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84857720240     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31823bc434     Document Type: Article

References (54)

1. Lee KR, Tavassoli FA, Prat J, et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: Tavassoli FA, Devilee P, eds. Surface Epithelial-Stromal Tumors. Lyon: IARC Press; 2003:117-145.
2. Silverberg SG, Kurman RJ, Nogales F, et al. Pathology and Genetics of Tumours of the Breast and Female Genital Organs. In: Tavassoli FA, Devilee P, eds. Epithelial Tumors and Related Lesions. Lyon: IARC Press; 2003:221-232.
3. Aarnio M, Sankila R, Pukkala E, et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer. 1999;81:214-218. (Pubitemid 29144749)
4. An HJ, Kim KI, Kim JY, et al. Microsatellite instability in endometrioid type endometrial adenocarcinoma is associated with poor prognostic indicators. Am J Surg Pathol. 2007;31:846-853. (Pubitemid 47165137)
5. Barrow E, Robinson L, Alduaij W, et al. Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: A report of 121 families with proven mutations. Clin Genet. 2009;75:141-149.
6. Bonadona V, Bonaiti B, Olschwang S, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304-2310.
7. Boyd J. Molecular genetics of hereditary ovarian cancer. Oncology (Williston Park). 1998;12:399-406. (Pubitemid 128617828)
8. Broaddus RR, Lynch HT, Chen LM, et al. Pathologic features of endometrial carcinoma associated with HNPCC: A comparison with sporadic endometrial carcinoma. Cancer. 2006;106:87-94. (Pubitemid 43032552)
9. Brown GJ, St John DJ, Macrae FA, et al. Cancer risk in young women at risk of hereditary nonpolyposis colorectal cancer: implications for gynecologic surveillance. Gynecol Oncol. 2001;80: 346-349. (Pubitemid 32207533)
10. Caduff RF, Johnston CM, Svoboda-Newman SM, et al. Clinical and pathological significance of microsatellite instability in sporadic endometrial carcinoma. Am J Pathol. 1996;148:1671-1678. (Pubitemid 26135906)
11. Cai KQ, Albarracin C, Rosen D, et al. Microsatellite instability and alteration of the expression of hMLH1 and hMSH2 in ovarian clear cell carcinoma. Hum Pathol. 2004;35:552-559. (Pubitemid 38656938)
12. Catasus L, Bussaglia E, Rodrguez I, et al. Molecular genetic alterations in endometrioid carcinomas of the ovary: similar frequency of beta-catenin abnormalities but lower rate of microsatellite instability and PTEN alterations than in uterine endometrioid carcinomas. Hum Pathol. 2004;35:1360-1368. (Pubitemid 39601576)
13. Clarke B, Tinker AV, Lee CH, et al. Intraepithelial T cells and prognosis in ovarian carcinoma: novel associations with stage, tumor type, and BRCA1 loss. Mod Pathol. 2009;22:393-402.
14. Claus EB, Schildkraut JM, Thompson WD, et al. The genetic attributable risk of breast and ovarian cancer. Cancer. 1996;77: 2318-2324. (Pubitemid 26162426)
15. Crijnen TE, Janssen-Heijnen ML, Gelderblom H, et al. Survival of patients with ovarian cancer due to a mismatch repair defect. Fam Cancer. 2005;4:301-305. (Pubitemid 41795805)
16. Dellas A, Puhl A, Schraml P, et al. Molecular and clinicopathological analysis of ovarian carcinomas with and without microsatellite instability. Anticancer Res. 2004;24:361-369. (Pubitemid 38279733)
17. Domanska K, Malander S, Masback A, et al. Ovarian cancer at young age: the contribution of mismatch-repair defects in a population-based series of epithelial ovarian cancer before age 40. Int J Gynecol Cancer. 2007;17:789-793. (Pubitemid 47063326)
18. Garg K, Leitao MM Jr. Kauff ND, et al. Selection of endometrial carcinomas for DNA mismatch repair protein immunohistochemistry using patient age and tumor morphology enhances detection of mismatch repair abnormalities. Am J Surg Pathol. 2009; 33:925-933.
19. Garg K, Shih K, Barakat R, et al. Endometrial carcinomas in women aged 40 years and younger: tumors associated with loss of DNA mismatch repair proteins comprise a distinct clinicopathologic subset. Am J Surg Pathol. 2009;33:1869-1877.
20. Gras E, Catasus L, Arguelles R, et al. Microsatellite instability, MLH-1 promoter hypermethylation, and frameshift mutations at coding mononucleotide repeat microsatellites in ovarian tumors. Cancer. 2001;92:2829-2836. (Pubitemid 33091919)
21. Grindedal EM, Renkonen-Sinisalo L, Vasen H, et al. Survival in women with MMR mutations and ovarian cancer: A multicentre study in Lynch syndrome kindreds. J Med Genet. 2010;47:99-102.
22. Hampel H, Frankel W, Panescu J, et al. Screening for Lynch syndrome (hereditary nonpolyposis colorectal cancer) among endometrial cancer patients. Cancer Res. 2006;66:7810-7817. (Pubitemid 44289242)
23. Irving JA, Catasus L, Gallardo A, et al. Synchronous endometrioid carcinomas of the uterine corpus and ovary: Alterations in the betacatenin (CTNNB1) pathway are associated with independent primary tumors and favorable prognosis. Hum Pathol. 2005;36:605-619. (Pubitemid 40922566)
24. Jarvinen HJ, Renkonen-Sinisalo L, ktan-Collan K, et al. Ten years after mutation testing for Lynch syndrome: cancer incidence and outcome in mutation-positive and mutation-negative family members. J Clin Oncol. 2009;27:4793-4797.
25. Jensen KC, Mariappan MR, Putcha GV, et al. Microsatellite instability and mismatch repair protein defects in ovarian epithelial neoplasms in patients 50 years of age and younger. Am J Surg Pathol. 2008;32:1029-1037.
26. Kaneki E, Oda Y, Ohishi Y, et al. Frequent microsatellite instability in synchronous ovarian and endometrial adenocarcinoma and its usefulness for differential diagnosis. Hum Pathol. 2004;35:1484-1493. (Pubitemid 40017988)
27. Kehoe SM, Kauff ND. Screening and prevention of hereditary gynecologic cancers. Semin Oncol. 2007;34:406-410. (Pubitemid 47503272)
28. Kobayashi K, Sagae S, Kudo R, et al. Microsatellite instability in endometrial carcinomas: frequent replication errors in tumors of early onset and/or of poorly differentiated type. Genes Chromosomes Cancer. 1995;14:128-132.
29. Lancaster JM, Powell CB, Kauff ND, et al. Society of Gynecologic Oncologists Education Committee statement on risk assessment for inherited gynecologic cancer predispositions. Gynecol Oncol. 2007; 107:159-162. (Pubitemid 47575743)
30. Lindor NM, Petersen GM, Hadley DW, et al. Recommendations for the care of individuals with an inherited predisposition to Lynch syndrome: A systematic review. JAMA. 2006;296:1507-1517. (Pubitemid 44465515)
31. Liu J, Albarracin CT, Chang KH, et al. Microsatellite instability and expression of hMLH1 and hMSH2 proteins in ovarian endometrioid cancer. Mod Pathol. 2004;17:75-80. (Pubitemid 41656455)
32. Lu KH. Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Fam Cancer. 2008;7:53-58.
33. Lu KH, Dinh M, Kohlmann W, et al. Gynecologic cancer as a "sentinel cancer" for women with hereditary nonpolyposis colorectal cancer syndrome. Obstet Gynecol. 2005;105:569-574. (Pubitemid 40271224)
34. Lynch HT, Casey MJ, Snyder CL, et al. Hereditary ovarian carcinoma: heterogeneity, molecular genetics, pathology, and management. Mol Oncol. 2009;3:97-137.
35. Lynch HT, Harris RE, Lynch PM, et al. Role of heredity in multiple primary cancer. Cancer. 1977;40:1849-1854. (Pubitemid 8216956)
36. Malander S, Rambech E, Kristoffersson U, et al. The contribution of the hereditary nonpolyposis colorectal cancer syndrome to the development of ovarian cancer. Gynecol Oncol. 2006;101: 238-243.
37. Mecklin JP, Jarvinen HJ. Clinical features of colorectal carcinoma in cancer family syndrome. Dis Colon Rectum. 1986;29:160-164. (Pubitemid 16124067)
38. Pal T, Permuth-Wey J, Betts JA, et al. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases. Cancer. 2005;104:2807-2816. (Pubitemid 41798292)
39. Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet. 2009;105:103-104.
40. Resnick K, Straughn JM Jr. Backes F, et al. Lynch syndrome screening strategies among newly diagnosed endometrial cancer patients. Obstet Gynecol. 2009;114:530-536.
41. Resnick KE, Hampel H, Fishel R, et al. Current and emerging trends in Lynch syndrome identification in women with endometrial cancer. Gynecol Oncol. 2009;114:128-134.
42. Rosen DG, Cai KQ, Luthra R, et al. Immunohistochemical staining of hMLH1 and hMSH2 reflects microsatellite instability status in ovarian carcinoma. Mod Pathol. 2006;19:1414-1420. (Pubitemid 44624159)
43. Rubin SC, Blackwood MA, Bandera C, et al. BRCA1, BRCA2, and hereditary nonpolyposis colorectal cancer gene mutations in an unselected ovarian cancer population: relationship to family history and implications for genetic testing. Am J Obstet Gynecol. 1998;178: 670-677. (Pubitemid 28196872)
44. Scully RE, Young RH, Clement PB. Tumors of the Ovary, Maldeveloped Gonads, Fallopian Tube, and Broad Ligament. Washington, D.C.: Armed Forces Institute of Pathology; 1998:126.
45. Shia J, Black D, Hummer AJ, et al. Routinely assessed morphological features correlate with microsatellite instability status in endometrial cancer. Hum Pathol. 2008;39:116-125. (Pubitemid 350216167)
46. Soliman PT, Broaddus RR, Schmeler KM, et al. Women with synchronous primary cancers of the endometrium and ovary: do they have Lynch syndrome? J Clin Oncol. 2005;23:9344-9350.
47. Soliman PT, Slomovitz BM, Broaddus RR, et al. Synchronous primary cancers of the endometrium and ovary: A single institution review of 84 cases. Gynecol Oncol. 2004;94:456-462. (Pubitemid 39024553)
48. Sood AK, Holmes R, Hendrix MJ, et al. Application of the National Cancer Institute international criteria for determination of microsatellite instability in ovarian cancer. Cancer Res. 2001;61: 4371-4374. (Pubitemid 32685761)
49. Ueda H, Watanabe Y, Nakai H, et al. Microsatellite status and immunohistochemical features of ovarian clear-cell carcinoma. Anticancer Res. 2005;25:2785-2788. (Pubitemid 41044662)
50. Walsh MD, Cummings MC, Buchanan DD, et al. Molecular, pathologic, and clinical features of early-onset endometrial cancer: identifying presumptive Lynch syndrome patients. Clin Cancer Res. 2008;14:1692-1700. (Pubitemid 351469453)
51. Watson P, Butzow R, Lynch HT, et al. The clinical features of ovarian cancer in hereditary nonpolyposis colorectal cancer. Gynecol Oncol. 2001;82:223-228. (Pubitemid 32730595)
52. Watson P, Vasen HF, Mecklin JP, et al. The risk of extra-colonic, extra-endometrial cancer in the Lynch syndrome. Int J Cancer. 2008;123:444-449. (Pubitemid 351842032)
53. Zaino R, Whitney C, Brady MF, et al. Simultaneously detected endometrial and ovarian carcinomas: A prospective clinicopathologic study of 74 cases: A gynecologic oncology group study. Gynecol Oncol. 2001;83:355-362. (Pubitemid 33033079)
54. Zhai QJ, Rosen DG, Lu K, et al. Loss of DNA mismatch repair protein hMSH6 in ovarian cancer is histotype-specific. Int J Clin Exp Pathol. 2008;1:502-509.